Literature DB >> 25740244

Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300.

Sagar Uttarkar1, Sandeep Dukare1, Bertan Bopp2, Michael Goblirsch2, Joachim Jose2, Karl-Heinz Klempnauer3.   

Abstract

The transcription factor c-Myb is highly expressed in hematopoietic progenitor cells and controls the transcription of genes important for lineage determination, cell proliferation, and differentiation. Deregulation of c-Myb has been implicated in the development of leukemia and certain other types of human cancer. c-Myb activity is highly dependent on the interaction of the c-Myb with the KIX domain of the coactivator p300, making the disruption of this interaction a reasonable strategy for the development of Myb inhibitors. Here, we have used bacterial Autodisplay to develop an in vitro binding assay that mimics the interaction of Myb and the KIX domain of p300. We have used this binding assay to investigate the potential of Naphthol AS-E phosphate, a compound known to bind to the KIX domain, to disrupt the interaction between Myb and p300. Our data show that Naphthol AS-E phosphate interferes with the Myb-KIX interaction in vitro and inhibits Myb activity in vivo. By using several human leukemia cell lines, we demonstrate that Naphthol AS-E phosphate suppresses the expression of Myb target genes and induces myeloid differentiation and apoptosis. Our work identifies Naphthol AS-E phosphate as the first low molecular weight compound that inhibits Myb activity by disrupting its interaction with p300, and suggests that inhibition of the Myb-KIX interaction might be a useful strategy for the treatment of leukemia and other tumors caused by deregulated c-Myb. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740244     DOI: 10.1158/1535-7163.MCT-14-0662

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  25 in total

1.  Molecular Basis for the Mechanism of Constitutive CBP/p300 Coactivator Recruitment by CRTC1-MAML2 and Its Implications in cAMP Signaling.

Authors:  Michael David Clark; Ganesan Senthil Kumar; Ryan Marcum; Qianyi Luo; Yongbo Zhang; Ishwar Radhakrishnan
Journal:  Biochemistry       Date:  2015-08-21       Impact factor: 3.162

2.  The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.

Authors:  Xi Liu; Kathryn A Gold; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2015-05-20       Impact factor: 6.261

3.  Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Marco De Dominici; Patrizia Porazzi; Angela Rachele Soliera; Samanta A Mariani; Sankar Addya; Paolo Fortina; Luke F Peterson; Orietta Spinelli; Alessandro Rambaldi; Giovanni Martinelli; Anna Ferrari; Ilaria Iacobucci; Bruno Calabretta
Journal:  Cancer Res       Date:  2017-12-12       Impact factor: 12.701

4.  Dual Labeling of the CBP/p300 KIX Domain for 19 F NMR Leads to Identification of a New Small-Molecule Binding Site.

Authors:  Clifford T Gee; Keith E Arntson; Edward J Koleski; Rachel Lynn Staebell; William C K Pomerantz
Journal:  Chembiochem       Date:  2018-04-06       Impact factor: 3.164

5.  Dual Mechanism of Rag Gene Repression by c-Myb during Pre-B Cell Proliferation.

Authors:  Greg A Timblin; Liangqi Xie; Robert Tjian; Mark S Schlissel
Journal:  Mol Cell Biol       Date:  2017-05-31       Impact factor: 4.272

Review 6.  Directly targeting transcriptional dysregulation in cancer.

Authors:  Thomas J Gonda; Robert G Ramsay
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

7.  Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

Authors:  Johannes Zuber; Ruud Delwel; Leonie Smeenk; Sophie Ottema; Roger Mulet-Lazaro; Anja Ebert; Marije Havermans; Andrea Arricibita Varea; Michaela Fellner; Dorien Pastoors; Stanley van Herk; Claudia Erpelinck-Verschueren; Tim Grob; Remco M Hoogenboezem; François G Kavelaars; Daniel R Matson; Emery H Bresnick; Eric M Bindels; Alex Kentsis
Journal:  Cancer Discov       Date:  2021-05-12       Impact factor: 39.397

8.  Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.

Authors:  Sumiko Takao; Lauren Forbes; Masahiro Uni; Shuyuan Cheng; Jose Mario Bello Pineda; Yusuke Tarumoto; Paolo Cifani; Gerard Minuesa; Celine Chen; Michael G Kharas; Robert K Bradley; Christopher R Vakoc; Richard P Koche; Alex Kentsis
Journal:  Elife       Date:  2021-02-02       Impact factor: 8.713

9.  The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer Proliferation.

Authors:  Qiwen Kuang; Yuxiang Liang; Yangjia Zhuo; Zhiduan Cai; Funeng Jiang; Jianjiang Xie; Yu Zheng; Weide Zhong
Journal:  Onco Targets Ther       Date:  2021-05-24       Impact factor: 4.147

10.  C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.

Authors:  Maria V Yusenko; Amke Trentmann; Debora A Casolari; Luca Abdel Ghani; Mairin Lenz; Melanie Horn; Wolfgang Dörner; Stefan Klempnauer; Henning D Mootz; Maria Francisca Arteaga; Jan-Henrik Mikesch; Richard J D'Andrea; Thomas J Gonda; Carsten Müller-Tidow; Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  Oncogene       Date:  2021-05-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.